<DOC>
	<DOCNO>NCT02240667</DOCNO>
	<brief_summary>1600 AF patient receive Pradaxa VKA stroke prevention follow 12 month quarterly visit . Prescriptions , adverse event ( applicable ) reason definitive treatment discontinuation collect . At 6 month , patient adherence assess , use Morisky Score .</brief_summary>
	<brief_title>Drug Persistence/Adherence Patients Treated With Dabigatran VKA Stroke Prevention Non Valvular Atrial Fibrillation ( SPAF )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<criteria>Inclusion criterion : Newly prescribe treatment Pradaxa® ( dabigatran etexilate ) /VKA indication `` Stroke prevention nonvalvular atrial fibrillation '' ( AF ) respect indication contraindication describe respective Summary Product Characteristics Pradaxa® 110 mg 150 mg hard capsule appropriate VKA ( patient eligible Pradaxa® VKA therapy ) . Treatment dabigatran etexilate VKA give accordance respective Summaries Product Characteristics . The routine diagnostic procedure treatment would undertake irrespective study unaffected . Only patient eligible therapy Pradaxa® therapy VKA accordance respective Summaries Product Characteristics document ( patient eligible VKA Pradaxa® ) Patients must sign patient consent form prior inclusion NIS . Exclusion criterion : Patients general special contraindication mention package leaflet Summary Product Characteristics must include . Patients participate time within last 30 day another NIS interventional clinical trial must include . Patients treat anticoagulant condition nonvalvular atrial fibrillation must include . Pradaxa® VKA use pregnancy lactation . Pregnant breastfeed woman must therefore included NIS .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>